Treatment of Orthostatic Hypotension

Stopped 1\. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt.

Conditions

• Autonomic Nervous System Diseases
• Orthostatic Hypotension
• Dopamine Beta-Hydroxylase Deficiency
• Orthostatic Intolerance

Interventions

• DRUG: Droxidopa Oral Product

Sponsor

Vanderbilt University

Collaborators

• [object Object]